Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer
NCT ID: NCT01012804
Last Updated: 2011-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2000-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at biomarkers in tissue samples from patients with metastatic colon cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
NCT00960427
Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy
NCT00280761
Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer
NCT01651026
Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer
NCT06114420
Exploratory Study of Intermittent Hypoxia Intervention on Colorectal Cancer
NCT06584318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the effect of surgical resection, in terms of physiological stress, on levels of tumor markers such as protein kinase A (PKA) expression in patients with metastatic colon cancer.
* Estimate variation among patients of baseline tumor markers in tumor tissue and sera.
* Correlate markers in tumor tissues with that in sera in these patients.
* Establish a tissue bank of these specimens for future studies.
OUTLINE: Biopsy and surgical specimens are obtained before and during standard surgery (patients may have had tumor tissue obtained before study entry and stored). Serum samples and tumor tissue are analyzed by immunohistochemistry and western blot. Tumor markers (such as PKA expression) are determined and marker levels are measured in serum samples and tissues.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
western blotting
immunohistochemistry staining method
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of colon cancer
* Metastatic disease for which surgical resection is indicated
* Metastatic disease accessible for tissue biopsy OR previously biopsied tissue is available
PATIENT CHARACTERISTICS:
* Platelet count ≥ 80,000/mm\^3
* INR ≤ 1.3
* PTT ≤ upper limit of normal
* No history of bleeding disorders or abnormal clotting factors
* No extrahepatic biliary obstruction
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Georgetown University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Georgetown University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John L. Marshall, MD
Role: STUDY_CHAIR
Lombardi Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GUMC-00074
Identifier Type: -
Identifier Source: secondary_id
NCI-G01-1992
Identifier Type: -
Identifier Source: secondary_id
CDR0000078662
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.